within Pharmacolibrary.Drugs.C_CardiovascularSystem.C01C_CardiacStimulantsExclCardiacGlycosides.C01CA28_Centhaquine;

model Centhaquine
  extends Pharmacolibrary.Drugs.ATC.C.C01CA28;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>C01CA28</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Centhaquine is a novel resuscitative agent developed for the treatment of hypovolemic shock. It acts as an alpha-adrenergic receptor agonist to increase venous return and improve cardiac output. Centhaquine has undergone phase 2 and phase 3 clinical trials for hypovolemic and hemorrhagic shock but is not widely approved or in routine clinical use globally.</p><h4>Pharmacokinetics</h4><p>No specific human pharmacokinetic studies or parameter values are published for centhaquine as of 2024. Estimates below are inferred from typical intravenous agent properties and available preclinical/clinical abstracts.</p><h4>References</h4><ol><li><p>O&#x27;Donnell, JN, et al., &amp; Scheetz, MH (2016). Pharmacokinetics of centhaquin citrate in a rat model. <i>The Journal of pharmacy and pharmacology</i> 68(1) 56–62. DOI:<a href=&quot;https://doi.org/10.1111/jphp.12498&quot;>10.1111/jphp.12498</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26725913/&quot;>https://pubmed.ncbi.nlm.nih.gov/26725913</a></p></li><li><p>O&#x27;Donnell, JN, et al., &amp; Scheetz, MH (2016). Pharmacokinetics of centhaquin citrate in a dog model. <i>The Journal of pharmacy and pharmacology</i> 68(6) 803–809. DOI:<a href=&quot;https://doi.org/10.1111/jphp.12554&quot;>10.1111/jphp.12554</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27109141/&quot;>https://pubmed.ncbi.nlm.nih.gov/27109141</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Centhaquine;
